Immunoregulation of carcinogenesis: Past, present, and future

Journal of the National Cancer Institute

Volumn 80, Issue 10, 1988, Pages 722-727

  Kripke, Margaret L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; HUMAN; IMMUNOSURVEILLANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY;

ANIMAL; HUMAN; IMMUNITY, CELLULAR; IMMUNOLOGIC SURVEILLANCE; IMMUNOSUPPRESSION; NEOPLASMS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023780207     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/80.10.722     Document Type: Review

References (67)

1. Ehruch P. Uber den jetzigen Stand der Karzinomforschung. In: Him- melweit F, ed. The collected papers of Paul Ehrlich, vol 11. London: Pergamon Press, 1957:550.
2. Thomas L. Reactions to homologous tissue antigens in relation to hypersensitivity. In: Lawrence HS, ed. Cellular and humoral aspects of the hypersensitive states. New York: Hoeber-Harper, 1959:529.
3. Burnet FM. Cancer—a biological approach IV. Practical applications. Br Med J 1957;1:844-847.
4. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
5. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol 1979;27:51-177.
6. Miller JFAP, Vadas MA, Whitelaw A, et al. Role of major histocompatibility complex gene products in delayed-type hypersensitivity. Proc NaU Acad Sci USA 1976;73:2486-2490.
7. Klein G. Tumor antigens. Annu Rev Microbiol 1966;20:223-252.
8. Old LJ, Boyse EA, Clarke DA, et al. Antigenic properties of chemically induced tumors. Ann NY Acad Sci 1962;101:80-106.
9. Baldwin RW. Tumor-specific immunity against spontaneous rat tumors. Int J Cancer 1966;1:257-264.
10. Gatti RA, Good RA. Occurrence of malignancy and immunodeficiency diseases: a literature review. Cancer 1971;28:89-98.
11. Stjernsward J. Immunosuppression by carcinogens. Antibiot Chemo- ther 1969;15:213-233.
12. Ball JK, Sinclair NR, McCarter JA. Prolonged immunosuppression and tumor induction by a chemical carcinogen injected at birth Science 1966;152:650-651.
13. Blair PB, Kripke ML, Lappe MA, et al. Immunologic deficiency associated with mammary tumor virus (MTV) infection in mice: hemagglutinin response and allograft survival. J Immunol 1971;106:364-370.
14. Salaman MIL Immunodepression by viruses. Antibiot Chemother 1969;15:393-406.
15. Kripke ML, Borsos T. Immunosuppression and carcinogenesis. A review. Isr J Med Sci 1974;10:888-903.
16. Carbone G, Parmiani G. Increased oncogenic effect of a low dose of methycholanthrene in immunodepressed mice. Tumori 1971^7:225- 231.
17. Bolton PM. The effect of immune depression on chemical carcinogenesis in the raL Oncology 1973;27:525-532.
18. Fraumeni JF Jr, Hoover R. Immunosurveillance and cancer epidemiologic observations. Natl Cancer Inst Mongr 1977;47:121-126.
19. Rygaard J, Povlsen CO. Is immunological surveillance not a cell- mediated immune function? Transplantation 1974;17:135-136.
20. Stutman O. Spontaneous, viral, and chemically induced tumors in the nude mouse. In: Fogh J, Giovanella B, eds. The nude mouse in experimental and clinical research. New York: Academic Press, 1978:411.
21. Ball JK. Immunosuppression and carcinogenesis: contrasting effects with 7,12-dimethylbenz[a]anthracene, benz[a]pyrene, and 3- methylcholanthrene. J Natl Cancer Inst 1970;44:1-10.
22. Stutman O. Immunological aspects of resistance to the oncogenic effect of 3-methylcholanthrene in mice. Isr J Med Sci 1973;9:217-228.
23. Allison AC. Potentiation of viral carcinogenesis by immunosuppression. Br Med J 1970;4:419-420.
24. Strayer DS, Skaletsky E, Sell S. Strain differences in Shope fibroma virus: an immunopathologic study. Am J Pathol 1984;116:342-358.
25. Klein G, Klein E. Immunosurveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci USA 1977;74:2121- 2125.
26. Law LW, Ting RC, Allison AC. Effects of antilymphocyte serum on tumor and leukaemia induction by murine sarcoma virus (MSV). Nature 1968;220:61-62.
27. Blair PB. Immunological aspects of the relationship between host and oncogenic virus in the mouse mammary tumor system. Isr J Med Sci 1971;7:161-186.
28. Allison AC, Taylor RB. Observations on thymectomy and carcinogenesis. Cancer Res 1967;27:703-707.
29. Kripke ML. Immunologic mechanisms in UV radiation carcinogenesis. Adv Cancer Res 1981;34:69-106.
30. Spellman CW, Daynes RA. Modification of immunologic potential by ultraviolet radiation, n. Generation of suppressor cells in short-term UV-irradiated mice. Transplantation 1977;24:120-126.
31. Fisher MS, Kripke ML Suppressor T lymphocytes control the development of primary skin cancers in ultraviolet-irradiated mice. Science 1982^216:1133-1134.
32. Phillips C, McMillan M, Flood PM, et al. Identification of unique tumor-specific antigens as a novel class I major histocompatibility molecule. Proc Natl Acad Sci USA 1985;82:5140-5144.
33. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for host defense against cancer based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 1976;33:241-259.
34. Purtulo DT. Biology of disease. Defective immune surveillance in viral carcinogenesis. Lab Invest 1984;51:373-385.
35. Braun DP, Harris JE. Relationship of leukocyte numbers, immunoreg- ulatory cell function, and phytohemagglutinin responses in cancer patients. JNCI 1981;67:809-814.
36. Allison AC. Immunological surveillance of tumors. Cancer Immunol Immunother 1977;2:151-155.
37. Den Otter W. Immune surveillance and natural resistance: an evaluation. Cancer Immunol Immunother 1986;21:85-92.
38. Hibbs JB Jr, Lambert LH Jr., Remington JS. Resistance to murine tumors conferred by chronic infection with intracellular protozoa. Toxoplasma gondii and Besnoida jeilisoni J Infect Dis 1971;124:587-592.
39. Hibbs JB Jr. Discrimination between neoplastic and non-neoplastic cells in vitro by activated macrophages. J Natl Cancer Inst 1974; 3:1487- 1492.
40. Hibbs JB Jr. Control of carcinogenesis: a possible role for the activatedmacrophage. Science 1972;177:998-1000.
41. Norbury KC, Kripke ML Ultraviolet-induced carcinogenesis in mice treated with silica, trypan blue or pyran copolymer. J Reticuloendothel Soc 1979;26:827-837.
42. Herberman RB. Possible role of natural killer cells and other effector cells in immune surveillance against cancer. J Invest Dermatol 1984;83 (suppl):137s-140s.
43. Brodt P, Gordon J. Natural resistance mechanisms may play a role in protection against chemical carcinogenesis. Cancer Immunol Immunother 1982;13:125-127.
44. Hanna N, Fidler U. Role of natural killer cells in the destruction of circulating tumor emboli. JNCI 1980;65:801-809.
45. Evans CH, DiPaolo JA. Lymphotoxin: an anticarcinogenic lymphokine as measured by inhibition of chemical carcinogen or ultraviolet- irradiation-induced transformation of Syrian hamster cells. Int J Cancer 1981;27:45-49.
46. Ransom JH, Evans CH, Jones AE, et al. Control of the carcinogenic potential of "“Technetium by the immunologic hormone lymphotoxin. Cancer Immunol Immunother 1983;15:126-130.
47. Fisher ER, Fisher B, Saffer E. The regional lymph node in cancer. Relationship of nodal histologic findings to cytotoxicity and immunity. Arch Pathol Lab Med 1977;101:152-155.
48. Anderson TM, Ibayashi Y, Holmes EC, et aL Modification of natural killer activity of lymphocytes infiltrating human lung cancers. Cancer Immunol Immunother 1987;25:65-68.
49. DeLustro F, Haskill JS. In situ cytotoxic T cells in a methyl- cholanthrene-induced tumor. J Immunol 1978;121:1007-1009.
50. Lill PH, Fortner GW. Identification and cytotoxic reactivity of inflammatory cells recovered from progressing or regressing syngeneic UV-induced murine tumors. J Immunol 1978;121:1854-1860.
51. Guy-Grand D, Griscelu C, Bassili P. The gut-associated lymphoid system: nature and properties of the large dividing cells. Eur J Immunol 1974;4:435-443.
52. Streilein JW. Lymphocyte traffic, T cell malignancies and the skin. J Invest Dermatol 1978;71:167-171.
53. Bienenstock J, Johnston H, Perey DYE. Bronchial lymphoid tissue. I. Morphologic characteristics. Lab Invest 1979;28:686-696.
54. Olsen GN, Gangemi JD. Bronchoalveolar lavage and the immunology of primary lung cancer. Chest 1985;87:677-683.
55. Manifold IH, Triger DR, Underwood JC. Kupffer cell depletion in chronic liver disease: implications for hepatic carcinogenesis. Lancet 1983;2:431-433.
56. Romerdahl CA, Kripke ML Advances in the immunobiology of the skin. Implications for cutaneous malignancies. Cancer Metastasis Rev 1986;5:167-178.
57. Toews GB, Bergstresser PR, Streilein JW. Epidermal Langerhans cell density determines whether contact hypersensitivity or unresponsiveness follows skin painting with DNFB. J Immunol 1980;124:445- 453.
58. Muller HK, Halliday GM, Knight BA. Carcinogen-induced depletion of cutaneous Langerhans cells. Br J Cancer 1985;52:81-85.
59. Elmets CA, Bergstresser PR, Tigelaar RE, et al. Analysis of the mechanism of unresponsiveness produced by haptens painted on skin exposed to low dose ultraviolet radiation. J Exp Med 1983; 158:781- 794.
60. Halliday GM, Muller HK. Induction of tolerance via skin depleted of Langerhans cells by a chemical carcinogen. Cell Immunol 1986;99:220-227.
61. Borden EC. Progress toward therapeutic application of interferons, 1979-1983. Cancer 1984;54:2770-2776.
62. Cheever MA, Greenberg PH, Fefer A, et al. Augmentation of the antitumor therapeutic efficacy of long term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med 1982;155:968- 980.
63. Fidler U, Sone S, Fogler WE, et aL Eradication of spontaneous metas- tases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 1981;78:1680-1684.
64. Boon T. Antigenic tumor cell variants obtained with mutagens. Adv Cancer Res 1983;39:121-151.
65. Kobayashi H. Viral xenogenization of intact tumor cells. Adv Cancer Res 1979;30:279-299.
66. Drebin JA, Link VC, Weinberg RA, et al. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Nad Acad Sci USA 1986;83:9129-9133.
67. Yuspa SH. Cutaneous chemical carcinogenesis. J Am Acad Dermatol 1986;15:1031-1044.